GlassScriptPhysician profile
Irshad Ahmed
NPI 1083683528
$730.96
in general payments reported to CMS, 2019-2025
11 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.75 · 2021: $144 · 2023: $236 · 2024: $191 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $150.06 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $127.45 | 2019-2025 | Breztri |
| Seagen INC. | $125.00 | 2021 | |
| Novo Nordisk INC | $85.22 | 2023-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $78.89 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $76.93 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Boston Scientific Corporation | $24.57 | 2023 | Watchman Flx |
| Amarin Pharma, INC. | $19.49 | 2021 | |
| Concordia Pharmaceuticals INC. | $14.86 | 2019 | |
| Pfizer INC. | $14.25 | 2023 | |
| Dexcom, INC. | $14.24 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irshad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.